spebrutinib (Compound)

Synonyms:AVL-292, spebrutinib, 1202757-89-8, cc-292, Btk inhibitor CC-292, AVL292, Spebrutinib [USAN:INN], UNII-DRU6NG543J, DRU6NG543J, N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide, N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide, Spebrutinib (AVL-292), n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide, C22H22FN5O3, AVL 292, N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide, 2-Propenamide, N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)-4-pyrimidinyl)amino)phenyl)-, CC-292 (AVL-292), N-{3-[(5-FLUORO-2-{[4-(2-METHOXYETHOXY)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENYL}PROP-2-ENAMIDE, N-(3-((5-Fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)-4-pyrimidinyl)amino)phenyl)-2-propenamide, SPEBRUTINIB [INN], Spebrutinib (USAN/INN), SPEBRUTINIB [USAN], SPEBRUTINIB [WHO-DD], SCHEMBL626216, GTPL7837, CHEMBL3301625, AMY9065, EX-A255, LMK-435, DTXSID101026012, HMS3653E15, HMS3674E05, BCP07702, BDBM50161162, CC 292, MFCD25976876, NSC780020, s7173, AKOS026670200, AKOS032949981, CCG-268921, CS-1482, DB11764, NSC-780020, SB14609, NCGC00386306-03, NCGC00386306-06, AC-32618, AS-16998, DA-35316, HY-18012, FT-0751022, SW219474-1, D10730, Q27088846, 3-(5-FLUORO-2-(4-(2-METHOXYETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)PHENYL)ACRYLAMIDE, N-(3-((5-fluoro-2-((4-(2-methoxyethoxyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide, N-(3-{5-fluoro-2-[4-(2-methoxy-ethoxy)-phenylamino]-pyrimidin-4-ylamino}-phenyl)-acrylamide

Pubchem:PUBCHEM:59174488

Id:b3d936c4-261b-5a06-a9b2-fec90a609bde

Description:nan